After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice

Phase 3psilocybinPositive

AI Analysis

Summary

Psilocybin demonstrated promise in mouse models for preventing chemotherapy-induced peripheral neuropathy, a condition affecting 30-50% of chemotherapy patients. The compound is currently in Phase 3 trials for depression with potential market availability by 2027.

Clinical Trial Data

Phase

Preclinical (mouse model)

Outcome Details

Preclinical data in mice showing promise for CIPN prevention; Phase 3 trials ongoing in depression with potential availability by 2027

Importance:4/10

Sentiment:

0.60

psilocybinCIPNchemotherapyneuropathypreclinicalPhase 3depression

Related Companies

$TRAX

Read the original article

Published by Drug Discovery & Development on September 8, 2026 4:17 PM

Read Original